Blood as a target for adjuvant therapies, such as 'purification methods' , for the treatment of acute infl ammation related to severe infection has been proposed for many years, even with relatively low levels of proof [1] [2] [3] [4] . Arguments for such an approach can be summarized as follows: almost all markers and cell phenotypes have been studied in blood; ex vivo studies using plasma from severe septic patients induce healthy cell phenotype changes mimicking those observed in septic cells [5] ; plasma ultra-fi ltrate coming from septic patients induces ex vivo modifi cation of cell functions [6] ; and plasmapheresis therapy has been shown to be effi cient at controlling auto-immune disease [7] . If these blood purification techniques are technically feasible, the mechanism(s) by which they can improve outcome remains unclear, and the goals of these techniques have to be clarifi ed: reduction of activated circulating cells and/or removal of mediators, or a combination of the two, need to be clearly demonstrated [8] . is key question guides development of the technical strategy to achieve this goal: cell reduction requires supports for trapping cells while mediator removal requires membranes that adsorb mediators or allow them to cross [9] . Since sepsis mechanisms are still incompletely understood, particularly the impact of changing the levels of mediators on outcome, it is diffi cult to defi ne the adequate support and methods. In addition, infl ammatory patterns during sepsis are not stable over time, moving rapidly from hyper-infl amma tion to immune-suppression [10] . e article from Rimmelé and colleagues [11] reports the consequences on cytokine profi les and cell-cell interactions of an ex vivo device to capture blood leukocytes and cytokines in blood from septic patients compared to healthy volunteers. is experiment reveals new information using a whole blood heparinized circulation device, with two diff erent hemoadsorption devices (cytosorb with large polystyrene beads, cytosorb with small polystyrene beads) compared to a hemofi lter (Oxiris®, Gambro-Hospal) as a control, fl owing at 0.75 ml/minute. e surface polarity was modifi ed to obtain a positively charged membrane to catch negatively charged endotoxins, when contact area was small for large beads. Using electron microscopy and immunofl uorescence staining with confocal imaging, leukocyte capture can be character ized. Plasma cytokine levels were determined by the luminex technique, allowing a large panel of mediators to be measured. A large panel of leukocyte surface markers was studied by fl ow cytometry and appropriate antibodies. It was then possible to assess the eff ects of leukocyte removal on infl ammation and immune func tion. e authors concluded that monocyte and leukocyte capture results in upregulation of interleukin-8 modula tion of Abstract After numerous negative randomized trials testing drugs for severe sepsis and/or septic shock, the blood puri cation approach remains one possibility. Many techniques have been proposed, having in common the goal to eliminate blood and/or plasma factors, supposed to play a negative role in outcomes. Among these, high dose of hemo ltration, high volume hemo ltration, high permeability hemo ltration and speci c or non-speci c hemoperfusion or hemoadsorption have been proposed. Until now, a poor level of proof has been published, questioning the pertinence of such a strategy. To have a chance to succeed, immune monitoring has to be performed to select suitable patients regarding their immune status, the intensity of in ammation and their cellular function. Because of the potential interaction with mediators and cell capture, Rimmelé and colleagues published the results obtained with an in vitro set up, testing di erent adsorption cartridges in comparison to hemo ltration. They nicely con rmed the complex impact on mediator levels and cell capture and phenotype. This is certainly a more systematic approach to better understand the action of such adsorbing cartridges, which has to be developed.
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cell-mediated immunity. Both aspects, cell capture and mediator removal or release, appear feasible, but have to deal with time-dependent changes in the immune profi le and also with the characteristics of circulating cells. Recent studies on functional genomic [12] and blood and tissue infi ltrating immune cells [13] strongly suggest that the initial phase of sepsis or acute infl am mation has a short duration, rapidly followed by quasi-constant immune depression during acute infl ammation. Such induced immunodepression concerns all aspects of the infl ammatory response, especially involving neutro phils, monocytes, and lymphocytes. e cell number, their function and life span become largely modifi ed [9] , with increasing life span of neutrophils, reduced function of monocytes and reduced life span and function of lymphocytes. e latter eff ect concerns the entire lymphocyte repertoire, except CD4+CD25+foxP3+ cells [14, 15] . ese observations question the timing for using hemoadsorption in severe sepsis, since the delay between the onset of sepsis and a therapeutic decision might be highly variable. Looking at the results obtained, such an extracorporeal device seems to perform well and is a promising method. For clinical use, it will then be essential to determine which patients, when, and for how long this strategy has to be applied. Such goals necessitate easy and repetitive immune monitoring, a major step to clarify. In addition, such a device has to work enough to overcome whole body production of mediators and cell phenotype changes. Considering the more or less selective removal of cells and mediators, the question might be: can plasmapheresis be a good alternative, especially if albumin is used as a replacement fl uid? is hypothesis might be supported by the recently reported results of an Italian randomized clinical trial on albumin (Albios). e fi rst report at the SMART meeting in May showed an outcome benefi t in septic shock patients treated with albumin at a dose to obtain a plasma level close to 30 g/ml.
